Early tacrolimus with half-matched stem cell transplant for blood cancer
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that needs a stem cell transplant.
- You need a relative who is a half-match (shares 5 to 8 out of 10 HLA markers) and willing to donate stem cells.
- This must be your first stem cell transplant from a donor (prior own-stem-cell transplant is okay).
- You must be physically active enough to care for yourself (Karnofsky score 70% or higher).
- Your heart, lungs, liver, and kidneys must work well enough for transplant.
- If you are a person who can become pregnant, you must not be pregnant and must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
Hear when a new Hematologic Disease and Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.